The Key Parameters that Drive Positive HTA Decisions
Monday 8th December 2025 12:00 - 13:00 (GMT)
Understand what truly matters to HTA bodies and how to optimise your value proposition
Masterclass Details:
What do Health Technology Assessment bodies look for when reviewing new medicines? In this 60-minute masterclass, Professor Panos Kanavos from the London School of Economics shares a concise framework for understanding the key parameters that underpin a positive HTA outcome.
Drawing on real-world examples and international case studies, Panos will explore how different types of value are assessed including clinical effectiveness, economic benefit and social impact. He’ll also explain how factors such as trial design, surrogate endpoints, disease severity, unmet need and comparator positioning can affect your case.
Whether you work in global market access, policy or evidence generation, this is a rare opportunity to learn directly from a leading academic and advisor in the HTA field. Join live to ask your questions and build sharper, more aligned evidence plans.
Join live to ask questions, test assumptions and take away evidence-based strategies that resonate with HTA audiences.
Key Learning Objectives:
- Understand the multi-dimensional value drivers that influence HTA decisions
- Explore how clinical, economic and social value are assessed in real-world reviews
- Learn how trial design and endpoint selection affect value perception
- Identify strategies to position your treatment against current standards of care
- Analyse the role of unmet need, disease severity and therapeutic context in value discussions
- Gain insight from a leading academic expert, with global experience and real-world examples
Can’t make the date? Register and we’ll send you a link to the recording so you can watch it on demand in your own time.
-
Date and time
8th Dec 2025 12:00 – 13:00 (GMT)
